NASDAQ · PCRX
Healthcare · Drug Manufacturers - Specialty & Generic
$25.05
Down-$0.29 (-1.16%)
Updated Oct 7, 2026, 1:47 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PCRX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
PCRX closed at $25.05 after 20 trading sessions, down 3.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $25.37 | $25.71 | $24.83 | $25.05 | 560.25K |
| Oct 2, 2026 | $25.04 | $25.66 | $24.66 | $25.21 | 469.79K |
| Oct 1, 2026 | $25.05 | $25.38 | $24.925 | $25.01 | 510.6K |
| Sep 30, 2026 | $25.59 | $25.77 | $24.905 | $25.05 | 628.47K |
| Sep 29, 2026 | $25.30 | $25.67 | $25.13 | $25.65 | 643.6K |
| Sep 28, 2026 | $25.15 | $25.76 | $24.79 | $25.39 | 483.06K |
| Sep 25, 2026 | $25.50 | $25.66 | $25.00 | $25.12 | 444.23K |
| Sep 24, 2026 | $24.58 | $25.60 | $24.50 | $25.56 | 725.15K |
| Sep 23, 2026 | $25.00 | $25.205 | $24.51 | $24.63 | 450.69K |
| Sep 22, 2026 | $24.36 | $24.965 | $24.20 | $24.70 | 380.5K |
| Sep 21, 2026 | $24.79 | $24.985 | $23.98 | $24.11 | 375.53K |
| Sep 18, 2026 | $24.36 | $24.72 | $24.20 | $24.69 | 680.88K |
| Sep 17, 2026 | $25.11 | $25.195 | $24.45 | $24.48 | 393.79K |
| Sep 16, 2026 | $24.06 | $24.91 | $24.06 | $24.91 | 759.13K |
| Sep 15, 2026 | $24.63 | $24.94 | $23.65 | $24.08 | 824.51K |
| Sep 14, 2026 | $25.71 | $25.99 | $24.65 | $24.68 | 418.44K |
| Sep 11, 2026 | $25.43 | $25.57 | $25.18 | $25.36 | 538.04K |
| Sep 10, 2026 | $25.92 | $25.995 | $25.10 | $25.16 | 733.77K |
| Sep 9, 2026 | $25.62 | $25.88 | $25.13 | $25.88 | 571.74K |
| Sep 8, 2026 | $25.98 | $26.41 | $25.675 | $25.87 | 386.42K |
The latest Smart Investors Daily articles mentioning PCRX.
Company
Market Activity
Research & News
PCRX research
Company profile and research snapshot.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | Outperform | — |
| Sep 9, 2026 | Leerink Partners | Market Perform | — |
| Aug 5, 2026 | Needham | Buy | — |
| Aug 5, 2026 | RBC Capital | Sector Perform | — |
| Jul 1, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 23, 2026
Oppenheimer analyst Les Sulewski initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Outperform rating and announces Price Target of $32.
ChartMill · Sep 11, 2026
Pacira Biosciences (PCRX) trades deeply below earnings and cash flow peers, backed by solid finances but slow growth in non-opioid pain care.
Yahoo · Sep 9, 2026
BRISBANE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on September 2, 2026 to five new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing R
Benzinga · Sep 9, 2026
Leerink Partners analyst Daniel Clark initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Market Perform rating and announces Price Target of $28.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PCRX.
